Epsilon M&A Deal Report - Takeda Pharmaceutical's OTC and prescription pharmaceutical products in Europe
Transaction Multiples for the Valuation of Private Companies
Orifarm Group / Takeda Pharmaceutical's OTC and prescription pharmaceutical products in Europe
No EMAT :
113870
Announced Date :
24/04/2020
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Orifarm Group
Target :
Takeda Pharmaceutical's OTC and prescription pharmaceutical products in Europe
Country :
Europe
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
Business Description :
Takeda Pharmaceutical's OTC and prescription pharmaceutical products (sold in Europe) portfolio includes: 130 OTC products, food supplements as well as select prescription products in the...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|||||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
| Date | Acquirer | Target | Country | Multiples | See details |
| 10/11/2020 | Cooper Consumer Health | Laboratoire Tradiphar | Nord | ** | 113842 |
| 29/03/2018 | Cerba Healthcare International | Histalim | Hérault | ** | 113797 |
Source: Epsilon Research / EMAT
